The TATTON trial [71] demonstrated the clinical benefits of osimertinib plus savolitinib in patients with previously treated EGFR-mutant MET-amplified NSCLC, with an objective response rate (ORR) of 44%. This evidence concerns the gene EGFR and non-small cell lung carcinoma.